




- 01. main
- 02. pairwise
- 03. fixed-effects
- 04. nonimputed SDs
- 05. $r=0.25$
- 06. $r=0.75$
- 07. low/moderate RoB
- 08. nonassumed randomization
- 09. blinded trials
- 10. ITT
- 11. clinician ratings
- 12. ABC-L/SW
- 13. DSM/ICD
- 14. >3 weeks
- 15. no genetic syndrome
- 16. no associated symptoms
- 17. more developed countries
- 18. low RoB (sequence/concealment)







- 01. main
- 02. pairwise
- 03. fixed-effects
- 04. nonimputed SDs
- 05. $r=0.25$
- 06. $r=0.75$
- 07. low/moderate RoB
- 08. nonassumed randomization
- 09. blinded trials
- 10. ITT
- 11. clinician ratings
- 12. DSM/ICD
- 13. >3 weeks
- 14. no genetic syndrome
- 15. no associated symptoms
- 16. more developed countries
- 17. including Nikvarz 2017
- 18. low ROB (sequence/concealment)




balovaptan




oxytocin









risperidone



sulforaphane



- 01. main
- 02. pairwise
- 03. fixed-effects
- 04. nonimputed SDs
- 05. $r=0.25$
- 06. $r=0.75$
- 07. low/moderate RoB
- 08. nonassumed randomization
- 09. blinded trials
- 10. ITT
- 11. clinician ratings
- 12. DSM/ICD
- 13. >3 weeks
- 14. no genetic syndrome
- 15. no associated symptoms
- 16. no developing country
- 17. low ROB (sequence/concealment)



effect_size
OR
RR

